Teikoku Pharma USA, Inc. Announces NMPA Approved Lidoderm® in China on May 8, 2024
- Written by PR Newswire
![]() |
SAN JOSE, Calif., May 30, 2024 /PRNewswire/ -- Teikoku Pharma USA (TPU) announced today that the NMPA (National Medical Products Administration) has approved Lidoderm® ("lidocaine 5% patch as lidocaine cataplasms") for the treatment of Post Herpetic Neuralgia (PHN) in China. TPU entered into an exclusive licensing agreement with Link...
Read more: Teikoku Pharma USA, Inc. Announces NMPA Approved Lidoderm® in China on May 8, 2024















